PA8599901A1 - PHARMACEUTICAL COMBINATION - Google Patents

PHARMACEUTICAL COMBINATION

Info

Publication number
PA8599901A1
PA8599901A1 PA20048599901A PA8599901A PA8599901A1 PA 8599901 A1 PA8599901 A1 PA 8599901A1 PA 20048599901 A PA20048599901 A PA 20048599901A PA 8599901 A PA8599901 A PA 8599901A PA 8599901 A1 PA8599901 A1 PA 8599901A1
Authority
PA
Panama
Prior art keywords
combination
pharmaceutical combination
eletriptan
prevention
treatment
Prior art date
Application number
PA20048599901A
Other languages
Spanish (es)
Inventor
Michael John Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8599901A1 publication Critical patent/PA8599901A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

EL PRESENTE INVENTO PROPORCIONA UNA COMBINACION DE (A) ELETRIPTAN, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, Y (B) BICARBONATO DE SODIO. LA COMBINACION PROPORCIONA UNA ABSORCION RAPIDA DE ELETRIPTAN CUANDO SE TOMA POR VIA ORAL. LA COMBINACION ES UTIL PARA EL TRATAMIENTO O LA PREVENCION DE UNA ENFERMEDAD PARA LA QUE ES INDICADO UN AGENTE AGONISTA DE 5-HT1, PARTICULARMENTE EN EL TRATAMIENTO DE UNA MIGRAÑA O PARA LA PREVENCION DE UNA RECURRENCIA DE MIGRANA.THIS INVENTION PROVIDES A COMBINATION OF (A) ELETRIPTAN, OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS, AND (B) SODIUM BICARBONATE. THE COMBINATION PROVIDES A FAST ABSORPTION OF ELETRIPTAN WHEN IT IS TAKEN BY ORAL. THE COMBINATION IS USEFUL FOR THE TREATMENT OR PREVENTION OF AN ILLNESS FOR WHICH A 5-HT1 AGONIST AGENT IS INDICATED, PARTICULARLY IN THE TREATMENT OF A MIGRAINE OR FOR THE PREVENTION OF A MIGRAN RECURRENCE.

PA20048599901A 2003-04-11 2004-04-07 PHARMACEUTICAL COMBINATION PA8599901A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
PA8599901A1 true PA8599901A1 (en) 2005-02-04

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048599901A PA8599901A1 (en) 2003-04-11 2004-04-07 PHARMACEUTICAL COMBINATION

Country Status (12)

Country Link
EP (1) EP1615635A1 (en)
JP (1) JP2006522790A (en)
AR (1) AR044009A1 (en)
BR (1) BRPI0409127A (en)
CA (1) CA2521902A1 (en)
MX (1) MXPA05010070A (en)
NL (1) NL1025908C2 (en)
PA (1) PA8599901A1 (en)
PE (1) PE20050086A1 (en)
TW (1) TW200423929A (en)
UY (1) UY28260A1 (en)
WO (1) WO2004089365A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
IT1393700B1 (en) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint SYNTHESIS OF 3 - {[(2R) -1-METHYLPYROLIDIN-2-IL] METHYL} -5- [2- (PHENILSULFONYL) ETYL] -1H-INDOL
JP6878021B2 (en) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 Pharmaceutical composition containing triptan and ascorbic acid
AU2019297360B2 (en) * 2018-07-03 2022-07-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (en) * 1986-08-01 1988-11-25 Zambon Spa PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (en) * 1993-03-26 1997-06-11 Zambon Spa PHARMECEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
CA2514875A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories International Srl Rapid absorption selective 5-ht agonist formulations

Also Published As

Publication number Publication date
TW200423929A (en) 2004-11-16
JP2006522790A (en) 2006-10-05
NL1025908C2 (en) 2005-11-22
AR044009A1 (en) 2005-08-24
BRPI0409127A (en) 2006-03-28
NL1025908A1 (en) 2004-10-13
UY28260A1 (en) 2004-11-30
WO2004089365A1 (en) 2004-10-21
CA2521902A1 (en) 2004-10-21
PE20050086A1 (en) 2005-03-01
EP1615635A1 (en) 2006-01-18
MXPA05010070A (en) 2005-11-23

Similar Documents

Publication Publication Date Title
CY1108725T1 (en) Combination of NMDA antagonist and acetylcholinesterase inhibitors for the treatment of ALZHEIMER
NO20082088L (en) Acetidines as MEK inhibitors for the treatment of proliferative diseases
HN2001000266A (en) SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS.
UY28285A1 (en) CONSUMABLE FILES BY ORAL ROUTE THAT DISSOLVES QUICKLY, CONTAINING A SWEETENER
CL2004000643A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A 5-HT 1B / 1D AGONIST AND A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR, USEFUL IN THE TREATMENT OF MIGRANE.
BR0307727A (en) Fomulation
CY1116023T1 (en) FORMS OF PHARMACEUTICAL DOSAGE CONTROLLED DETERMINATION WITH PHARMACEUTICAL DISSOLUTION LIMITATIONS
DOP2006000050A (en) A SOLID FORMULATION OF PHARMACEUTICAL DOSAGE
CY1109119T1 (en) PHARMACEUTICAL FORMS OF LONG-TERM RELEASE INCLUDING LAMOTRIGIN
AR062860A1 (en) THERAPEUTIC COMBINATIONS 482
NO20034433D0 (en) Atineoplastic compositions such as rapamycin with gemcitabine or fluorouracil
PA8637301A1 (en) DERIVATIVES OF AMINO-5, 5-DIFENYLIMIDAZOLONE FOR THE INHIBITION OF THE B-SECRETASE
UY27598A1 (en) PHARMACEUTICAL COMPOSITIONS OF ORXALLY ACTIVE TAXAN DERIVATIVES THAT HAVE IMPROVED BIODISPONIBILITY
PE20060594A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PPAR AGONIST
BR0316170A (en) Combination, pharmaceutical composition, use of a combination, and method for the prophylaxis or synergistic treatment of cancer.
CY1117060T1 (en) GRINDING PROCESS
CL2007002875A1 (en) Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms.
AR054253A1 (en) ASSOCIATION BETWEEN RAILWAY AND AN ARTEMISININE DERIVATIVE FOR THE TREATMENT OF PALUDISM
CL2007002381A1 (en) Use of compounds derived from 2,5-dihydroxybenzene susu salts, solvates or isomers and use of the combination with at least one compound selected from diclofenac, a corticosteroid, an antibiotic, an analgesic, an immunomodulator, among others, for treatment or prophylaxis of dermatitis
CR9385A (en) PREVENTIVE OR THERAPEUTIC AGENT FOR THE DISORDER OF THE DEPRESSION OR THE ANXIETY
PA8599901A1 (en) PHARMACEUTICAL COMBINATION
MY137620A (en) Therapeutic treatment
CR7648A (en) MICROCAPSULES FOR DELAYED AND CONTROLLED LIBERATION OF PERINDROPIL
AR046402A1 (en) COMBINATION OF ACTIVE PRINCIPLE THAT INCLUDES A 2,5-DIHYDROBENCENOSULPHONIC COMPOUND AND A POTASSIUM CHANNEL MODULATOR
CR9074A (en) AGENT FOR THE PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME